GB

C. Glenn Begley

MD PhD FRACP FRCPA FRCPath FAHMS

Dr C. Glenn Begley is a clinical haematologist and medical oncologist, whose academic and commercial roles include board level and senior positions in Australia, the USA and the UK.

Glenn has held many leadership positions in start-up and established biopharmaceutical companies, including CEO of BioCurate Pty Ltd., CSO at Akriveia Therapeutics (California), CSO at TetraLogic Pharmaceuticals (Pennsylvania), and from 2002-2012, Vice-President and Global Head of Hematology/Oncology Research at Amgen. During this time, he became interested in the issue of research integrity and scientific reproducibility.

Before joining Amgen, Glenn had over 20 years of clinical experience in medical oncology and hematology.  His personal research focused on regulation of hematopoietic cells and translational clinical trials.

Glenn studied Medicine at undergraduate and postgraduate level at The University of Melbourne.